PMV Pharmaceuticals Sees Decline in Short Interest

Shares of the cancer drug developer drop as short positions are reduced.

Mar. 17, 2026 at 3:40pm

Got story updates? Submit your updates here. ›

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company focused on developing treatments for p53 mutations in cancer, saw a significant 18% decline in short interest in February. As of February 27th, there were 1,232,783 shares sold short, down from 1,503,564 shares on February 12th. The days-to-cover ratio is currently 1.4 days, indicating the stock's short interest is relatively low.

Why it matters

Short interest can be an indicator of investor sentiment towards a company. The decline in short positions for PMV Pharmaceuticals suggests that some investors are becoming more bullish on the stock, potentially due to optimism around the company's pipeline of p53-targeting cancer therapies.

The details

PMV Pharmaceuticals' lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company is currently developing this tumor-agnostic therapy for various types of cancer. The drop in short interest may indicate growing confidence in the potential of PMV's pipeline among some investors.

  • As of February 27th, 2026, there was short interest totaling 1,232,783 shares.
  • This represents an 18% decline from the 1,503,564 shares that were sold short as of February 12th, 2026.

The players

PMV Pharmaceuticals, Inc.

A precision oncology company that is developing small molecule and tumor-agnostic therapies targeting p53 mutations in cancer.

PC14586

PMV Pharmaceuticals' lead product candidate, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

Got photos? Submit your photos here. ›

The takeaway

The decline in short interest for PMV Pharmaceuticals suggests that some investors are becoming more optimistic about the company's prospects, particularly around its lead p53-targeting cancer therapy candidate PC14586. However, the stock still has a 'Hold' rating from analysts, indicating a mixed outlook on the company's future performance.